3种不同化疗方案治疗套细胞淋巴瘤的疗效分析  

The comparison of efficacy of three regimens for mantle cell lymphoma

作　　者：陈捷[1] 田红[1] 吴颖[1] 李莉莉[1] 

机构地区：[1]南京军区福州总医院血液科,福州350025

出　　处：《临床血液学杂志》2008年第1期13-14,共2页Journal of Clinical Hematology

摘　　要：目的:探讨3种不同化疗方案治疗套细胞淋巴瘤(MCL)的临床效果。方法:19例确诊MCL患者,分别用3种不同的方案治疗。CHOP方案:初治患者13例,复发患者9例;单用福达拉宾4例,均为初治患者;美罗华加福达拉宾加环磷酰胺加米托蒽醌(R-FCM)方案治疗4例,均为复发患者。结果:CHOP方案:初治患者中政11例(84.6%)例有效,复发患者中1/9(11.1%)例有效;单用福达拉宾:4例均为初治患者,3例CR1例PR(75.0%)有效;R-FCM方案:4例均为复发的患者4/4(100%)例。结论:以CHOP为基础方案和单用福达拉宾对于初治的MCL均有较好的疗效,但是生存时间短,复发的患者单纯化疗效果不理想,加用美罗华可以明显提高治疗效果。Objective：To investigate more effective treatment for mantle cell lymphoma. Method： Nineteen patients were entered into the study. Among them, 13 patients with newly diagnosed MCI, and 9 relapsed patients were treated with CHOP; 4 newly diagnosed patients with fludarabine alone and 4 relapsed with rituximab combined with FCM （fludarabine, cyclophosphomide and mitoxantrone）. Result： 10/13 newly diagnosed patients and 1/9 relapsed patients with CHOP achieved response. The response showed in 3/4 patiens initially treated with fludarabine alone and 4/4 relapsed patients with rituximab ＋ FCM. Conclusion： It is appropriate to treat newly diagnosed MCL with CHOP-based regimen or fludarabine alone as frontline choice. But in relapsed patients, only chemotherapy is less effective and the addition of rituximab may achieve better result. Chemotherapy plus rituximab appears most promising for salvage therapy.

关 键 词：套细胞 淋巴瘤 福达拉宾 美罗华 

分 类 号：R733.4[医药卫生—肿瘤]